Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Dianthus Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 52 | 46 | −6 |
| Shares | 29.7M | 29.0M | −655.3K (−2.2%) |
| Value | $23.6M | $22.0M | −$1.56M (−6.6%) |
New holders (3)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nantahala Capital Management, LLC | 5,000,000 | $3.79M | 0.46% |
| Octagon Capital Advisors LP | 550,000 | $416.9K | 0.06% |
| XTX Topco Ltd | 26,932 | $20.4K | 0.00% |
Sold out (9)
Institutions that held Dianthus Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Lion Point Capital, LP | 4,558,466 | $3.62M |
| Western Standard LLC | 1,439,374 | $1.14M |
| TCW Group Inc | 750,000 | $596.0K |
| Marshall Wace, LLP | 157,670 | $124.6K |
| Bridgeway Capital Management, LLC | 152,700 | $121.4K |
| National Asset Management, Inc. | 13,800 | $11.0K |
| Virtu Financial LLC | 10,724 | $9.00K |
| Belpointe Asset Management LLC | 5,500 | $4.37K |
| FMR LLC | 254 | $202 |